Join to View Full Profile
1430 Tulane AvenueNew Orleans, LA 70112
Phone+1 504-988-5228
Dr. Boyce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jessica Boyce is a hematology-oncology fellow with a particular interest in clinical trials and translational medicine, particularly in relation to immuno-oncology and solid tumors, who is dedicated to evidence-based medicine, patient care and education, and medical advancement. In addition to working at outstanding institutions with diverse and complex patient populations across the US, has international clinical experience in both Australia and Ghana. Additionally, has strong work experience in clinical research and pharmaceutical development, both within industry and academia.
She received her M.D. from the University of Queensland in 2019, and completed her residency in internal medicine at Legacy Health in Portland, OR in 2023. She is currently pursuing a fellowship hematology-medical oncology at Tulane University in New Orleans, LA.
Education & Training
Tulane UniversityFellowship, Hematology and Medical Oncology, 2025 - 2028
Legacy Health/Emanuel Medical CenterResidency, Internal Medicine, 2020 - 2023
The University of Queensland Medical SchoolClass of 2019
Touro College of Osteopathic MedicineGraduate Studies, Medical Sciences, 2014 - 2015
University of Nevada RenoB.S., Biology, 2010 - 2011
Certifications & Licensure
LA State Medical License 2023 - 2026
OR State Medical License 2020 - 2023
American Board of Internal Medicine Internal Medicine
American Heart AssociationAdvanced Cardiovascular Life Support Experienced Provider (ACLS)- American Heart AssociationBasic Life Support for Healthcare Professionals (BLS)
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Start of enrollment: 2009 Sep 01
Publications & Presentations
Journal Articles
- Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literatureJessica Boyce, Karine Tawagi & John T. Cole, Journal of Medical Case Reports volume, 11/15/2020
- Immunotherapy Related Adverse Events Predict Treatment ResponseMaslov D, Thomas K, Simenson V, Sullivan C, Mohammed A, Boyce J, Matrana M, Journal of Cancer Treatment and Research, 6/9/2020
Abstracts/Posters
- Outcome and clinicopathologic/molecular characteristics of NSCLC with cutaneous, subcutaneous and/or muscular metastasesBoyce J, Wurtz A, Goldberg S, Chiang A, Wilson F, Duffield E, Davies M, Medow K, Dest V, Politi K, Schalper K, Herbst R, Gettinger S, IASLC- Targeted Therapies of Lung Cancer Meeting, 2/2022
Press Mentions
Primary Colon Adenocarcinoma with Choriocarcinoma Differentiation: A Case Report and Review of the LiteratureNovember 16th, 2020
Professional Memberships
- Society of Clinical Research AssociatesMember
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
